India to Uganda: Actinomycin Export Trade Route
India has recorded 22 verified shipments of Actinomycin exported to Uganda, representing a combined trade value of $37.6K USD. This corridor is served by 4 active Indian exporters, with an average shipment value of $1.7K USD. The leading Indian exporter is ZUVIUS LIFESCIENCES PRIVATE LIMITED, which accounts for 88% of total export value with 3 shipments worth $33.2K USD. On the buying side, ONCOPHARM SPECIALITY PHARMACY is the largest importer in Uganda with $33.2K USD in purchases. The top 3 suppliers — ZUVIUS LIFESCIENCES PRIVATE LIMITED, RMPL PHARMA LLP , RMPL PHARMA LLP — together control 97% of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to Uganda Actinomycin corridor is one of India's established pharmaceutical export routes, with 22 shipments documented worth a combined $37.6K USD. The route is dominated by ZUVIUS LIFESCIENCES PRIVATE LIMITED, which alone accounts for roughly 88% of all export value, reflecting the consolidated nature of India's actinomycin manufacturing sector.
Across 4 active suppliers, the average shipment value stands at $1.7K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 74% of all shipments, consistent with actinomycin's non-urgent bulk-order profile.
Shipment activity peaks during April–June, with an average transit time of 21 days port-to-port. The route has recorded an annual growth rate of 18.3%, placing it at rank #15 among India's top actinomycin export destinations globally.
On the import side, key buyers of Indian actinomycin in Uganda include ONCOPHARM SPECIALITY PHARMACY, TO THE ORDER OF INVOICE RAISED TO , INVOICE RAISED TO and 2 others. ONCOPHARM SPECIALITY PHARMACY is the single largest importer with 3 shipments valued at $33.2K USD.
Route Characteristics
- Average transit21 days
- Peak seasonQ2
- Primary modeSea freight
- Top portSAHAR AIR CARGO ACC (INBOM4)
Market Position
- Global rank#15
- Annual growth+18.3%
- Demand growth+15.7%
- Regulatory ease76/100
Top 10 Indian Actinomycin Exporters to Uganda
Showing top 10 of 4 Indian suppliers exporting Actinomycin to Uganda, ranked by total trade value (USD)
| Rank | Supplier (Indian Exporter) | Shipments | Total Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | ZUVIUS LIFESCIENCES PRIVATE LIMITED Avg $11.1K per shipment | 3 | $33.2K | 88.5% |
| 2 | RMPL PHARMA LLP Avg $442 per shipment | 5 | $2.2K | 5.9% |
| 3 | RMPL PHARMA LLP Avg $376 per shipment | 3 | $1.1K | 3.0% |
| 4 | EXSELL LABORATORIES PRIVATE LIMITED Avg $91 per shipment | 11 | $999 | 2.7% |
This table shows the top 10 of 4 Indian companies exporting actinomycin to Uganda, ranked by total trade value. The listed exporters are: ZUVIUS LIFESCIENCES PRIVATE LIMITED, RMPL PHARMA LLP , RMPL PHARMA LLP, EXSELL LABORATORIES PRIVATE LIMITED . ZUVIUS LIFESCIENCES PRIVATE LIMITED is the dominant supplier with 3 shipments worth $33.2K USD, giving it a 88% market share. The top 3 suppliers together account for 97% of the total trade value on this route.
Top 10 Actinomycin Importers in Uganda
Showing top 10 of 5 known buyers in Uganda receiving Actinomycin shipments from India, ranked by import value
On the receiving end of this trade route, the leading importers of Indian actinomycin in Uganda include ONCOPHARM SPECIALITY PHARMACY, TO THE ORDER OF INVOICE RAISED TO , INVOICE RAISED TO, FIRST PHARMACY (U) LTD , TO THE ORDER OF INVOICE RAISED TO. The largest importer is ONCOPHARM SPECIALITY PHARMACY, accounting for $33.2K USD across 3 shipments — representing 88% of all actinomycin imports from India on this route.
| Rank | Importer / Buyer | Shipments | Import Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | ONCOPHARM SPECIALITY PHARMACY | 3 | $33.2K | 88.5% |
| 2 | TO THE ORDER OF INVOICE RAISED TO | 5 | $2.2K | 5.9% |
| 3 | INVOICE RAISED TO | 2 | $1.1K | 2.9% |
| 4 | FIRST PHARMACY (U) LTD | 11 | $999 | 2.7% |
| 5 | TO THE ORDER OF INVOICE RAISED TO | 1 | $37 | 0.1% |
Top 10 Actinomycin Formulations Imported by Uganda
Showing top 10 of 10 product formulations shipped on the India to Uganda Actinomycin route, ranked by trade value
Uganda imports a wide range of actinomycin formulations from India, spanning tablets, capsules, suspensions, and combination drugs. The top formulation — DACTINOMYCIN 0.5MG INJ DACTINOZ 0.5MG I — accounts for $20.6K USD across 2 shipments. A total of 10 product variants have been identified in the shipment records.
| Rank | Product Formulation | Shipments | Trade Value (USD) | Market Share |
|---|---|---|---|---|
| 1 | DACTINOMYCIN 0.5MG INJ DACTINOZ 0.5MG I | 2 | $20.6K | 54.9% |
| 2 | DACTINOMYCIN 0.5MG INJ (DACTINOZ 0.5MG INJ),PACK-1 VIALVLS | 1 | $12.6K | 33.5% |
| 3 | COSMEDAC 0.5MG (DACTINOMYCIN) | 2 | $1.2K | 3.2% |
| 4 | COSMEDAC 0.5 MG VIAL DACTINOMYCIN 300 VIALS | 2 | $1.1K | 2.9% |
| 5 | DACTINOMYCIN FOR INJECTION 0.5MG | 9 | $846 | 2.3% |
| 6 | COSMEDAC 0.5MG (VIAL) (DACTINOMYCIN) (29 | 1 | $580 | 1.5% |
| 7 | COSMEDAC 0.5MG (DACTINOMYCIN) (200 VIALS | 1 | $407 | 1.1% |
| 8 | DACTINOMYCIN FOR INJECTION 0.5MG (PER VI | 2 | $152 | 0.4% |
| 9 | COSMEDAC 0 5MG VIAL DACTINOMYCIN BACTH NO DMI2237AAQ | 1 | $37 | 0.1% |
| 10 | COSMEDAC 0.5MG (VIAL) (DACTINOMYCIN) (5 | 1 | $12 | 0.0% |
Shipping & Logistics Analysis
Freight mode split and port-of-origin breakdown
Freight Mode Distribution
Sea freight dominates at 74%, typical for bulk pharmaceutical shipments.
Top Ports of Origin
SAHAR AIR CARGO ACC (INBOM4) handles the highest volume with 16 shipments. Transit time averages 21 days by sea.
Market Dynamics
India's actinomycin exports to Uganda are driven primarily by a handful of large-scale manufacturers. ZUVIUS LIFESCIENCES PRIVATE LIMITED with 3 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 4 active exporters signals a competitive but concentrated market — buyers in Uganda benefit from supplier diversity while the top tier handles the majority of volume.
The top 3 suppliers — ZUVIUS LIFESCIENCES PRIVATE LIMITED, RMPL PHARMA LLP , RMPL PHARMA LLP — together account for 97% of total trade value on this route. The average shipment value of $1.7K USD reflects a mix of bulk commercial orders and smaller specialty shipments.
Beyond the primary product category, shipments on this route include closely related formulations such as dactinomycin 0.5mg inj (dactinoz 0.5mg inj),pack-1 vialvls and cosmedac 0.5mg (dactinomycin) , suggesting that buyers in Uganda tend to consolidate orders across related product lines from the same Indian supplier.
On the buying side, ONCOPHARM SPECIALITY PHARMACY is the largest importer with 3 shipments worth $33.2K USD — representing 88% of all actinomycin imports from India on this route.
Route Statistics
- Trade Volume
- $37.6K
- Avg. Shipment
- $1.7K
- Suppliers
- 4
- Buyers
- 5
- Transit (Sea)
- ~21 days
- Annual Growth
- +18.3%
Related Analysis
Other Actinomycin Routes
Unlock the Full India to Uganda Actinomycin Dataset
TransData Nexus provides verified shipment-level records, supplier contact details, HS code breakdowns, real-time pricing benchmarks, and regulatory compliance guides for 22 shipments on this route.
Live Corridor Intelligence
India → Uganda trade corridor intelligence
1Live Corridor Intelligence
As of March 2026, the India-Uganda pharmaceutical trade corridor is experiencing significant disruptions due to escalating tensions in the Middle East. These conflicts have led to rerouting of shipping vessels, particularly around the Red Sea and Suez Canal, resulting in extended transit times and increased freight costs. Maritime carriers have suspended bookings and diverted ships around the Cape of Good Hope, elongating lead times and pressurizing Suez-linked lanes. This has disproportionately impacted time-sensitive pharmaceutical shipments, including formulations containing Actinomycin.
Freight rates have surged, with transport charges nearly doubling and additional surcharges ranging from $4,000 to $8,000 per shipment. Air cargo options are also constrained due to regional airspace closures, leading to longer routings and further delays.
Currency fluctuations have added another layer of complexity. The Indian Rupee (INR) has experienced volatility against the Ugandan Shilling (UGX), affecting pricing and profitability for exporters and importers. Additionally, recent trade policy changes, including new tariffs and port fees, have introduced further costs and uncertainties into the trade corridor.
Geopolitical & Sanctions Impact
India → Uganda trade corridor intelligence
1Geopolitical & Sanctions Impact
Geopolitical tensions, particularly in the Middle East, have significantly impacted shipping routes between India and Uganda. Conflicts in the region have led to the closure of key maritime routes, necessitating longer and more expensive alternative paths. This has resulted in increased insurance premiums and freight rates, directly affecting the cost and reliability of pharmaceutical exports.
Global conflicts, such as those in Ukraine, have further strained international shipping and logistics, contributing to the volatility in freight rates and insurance costs. The cumulative effect of these geopolitical factors has been a disruption in the timely delivery of pharmaceutical products, including Actinomycin formulations, to Uganda.
Trade Agreement & Policy Analysis
India → Uganda trade corridor intelligence
1Trade Agreement & Policy Analysis
As of early 2026, there is no specific Free Trade Agreement (FTA) between India and Uganda. However, both nations have engaged in bilateral discussions to enhance trade relations. Notably, the third session of the India-Uganda Joint Trade Committee was held on March 25-26, 2025, in New Delhi. During this meeting, both sides agreed to explore Memorandums of Understanding (MoUs) for recognition of Indian Pharmacopoeia and cooperation in various sectors, including pharmaceuticals.
While no formal FTA exists, these discussions indicate a mutual interest in strengthening trade ties, which could positively impact the pharmaceutical trade corridor in the future.
Landed Cost Breakdown
India → Uganda trade corridor intelligence
1Landed Cost Breakdown
Estimating the landed cost components for Actinomycin formulations shipped from India to Uganda involves several factors:
- FOB Price: The Free on Board (FOB) price for Actinomycin formulations varies depending on the manufacturer and specific product. For estimation purposes, assume an average FOB price of $100 per unit.
- Sea Freight Cost per Container: Due to current disruptions, sea freight costs have nearly doubled. Assuming a 20-foot container can hold approximately 10,000 units, the freight cost per container is estimated at $8,000, translating to $0.80 per unit.
- Insurance: With increased risks, insurance premiums have risen. Assuming an insurance rate of 1% of the FOB value, the insurance cost per unit is $1.00.
- Customs Duty: Uganda's customs duty on pharmaceutical products is typically low or exempt to encourage healthcare access. Assuming a 0% duty, the cost per unit remains $0.00.
- Clearance Charges: Customs clearance and handling charges in Uganda are estimated at $500 per container, equating to $0.05 per unit.
- VAT/GST: Uganda imposes a Value Added Tax (VAT) of 18% on most goods. Applying this to the CIF (Cost, Insurance, and Freight) value per unit ($101.80), the VAT per unit is $18.32.
- Local Distribution: Costs associated with local distribution, including transportation and warehousing, are estimated at $0.50 per unit.
Total Landed Cost per Unit:
- FOB Price: $100.00
- Sea Freight: $0.80
- Insurance: $1.00
- Customs Duty: $0.00
- Clearance Charges: $0.05
- VAT: $18.32
- Local Distribution: $0.50
Total: $120.67
Please note that these figures are estimates based on current data and may vary depending on specific circumstances and market conditions.
Uganda Pharmaceutical Import Regulations
National DRA registration, GMP, and compliance requirements for Indian exporters
1National DRA Registration & Import Requirements
Importers must possess a valid pharmacy operating license and an import license issued by the NDA. The import license is valid for one calendar year. Each drug consignment requires a Verification Certificate from the NDA prior to importation. (nda.or.ug)
Product registration involves submitting a Common Technical Document (CTD) dossier. The registration fee for imported human drugs is $1,250, with an annual retention fee of $500. (businesslicences.go.ug)
Foreign manufacturing sites must undergo NDA inspections to ensure compliance with Good Manufacturing Practice (GMP) standards. The NDA conducts risk-based inspections of both domestic and foreign manufacturing sites. (nda.or.ug)
2Quality & GMP Standards for Indian Exporters
Indian manufacturers exporting Actinomycin formulations to Uganda must comply with NDA's GMP guidelines. This includes obtaining GMP certification from the NDA, which involves an inspection of the manufacturing facility. (nda.or.ug)
As of December 2025, Ciron Drugs and Pharmaceuticals Limited, located in Maharashtra, India, is listed among NDA's GMP-compliant facilities. (nda.or.ug)
The NDA maintains a system of post-marketing surveillance and risk assessment programs to identify quality concerns. Enforcement actions may include warning letters, formal cautions, suspension, revocation, or variation of authorizations held by manufacturers and distributors. (nda.or.ug)
3Recent Regulatory Developments (2024-2026)
In August 2023, the NDA revised its GMP guidelines for medicinal products, effective from September 6, 2023. These guidelines provide updated requirements for pharmaceutical manufacturers to comply with GMP standards. (nda.or.ug)
In December 2025, the NDA published the "National Drug Policy and Authority (Fees) (Amendment) Regulations 2025," outlining updated fees for drug registration, retention, and other regulatory services. (nda.or.ug)
In November 2025, the NDA released guidelines on the verification of applications for the importation and exportation of drugs, pharmaceutical raw, and packaging materials. These guidelines detail the requirements and procedures for obtaining import and export permits. (nda.or.ug)
These developments reflect the NDA's ongoing efforts to enhance regulatory frameworks and ensure the quality and safety of pharmaceutical products in Uganda.
Uganda Actinomycin Market Context & Tariffs
Market size, import duties, and competitive landscape · MFN tariff: The Most-Favored-Nation (MFN) import duty rate for HS code 30049046 in Uganda is 0%.
1Uganda Actinomycin Market Size & Demand
Actinomycin formulations are primarily utilized in the treatment of various cancers, including Wilms' tumor, rhabdomyosarcoma, and Ewing's sarcoma. In Uganda, the prevalence of these cancers has been increasing, leading to a heightened demand for effective chemotherapy agents. The country's healthcare expenditure has been on an upward trajectory, with a significant portion allocated to oncology treatments. While specific data on the market size for Actinomycin formulations in Uganda for 2024-2025 is limited, the rising incidence of cancer and increased healthcare spending suggest a growing market. Uganda relies heavily on imports for its pharmaceutical needs, including Actinomycin formulations, due to limited domestic manufacturing capabilities in this specialized sector.
2Import Tariff & Duty Structure
Uganda imposes a 0% import duty on pharmaceutical products classified under HS code 30049046, which includes finished Actinomycin formulations. Additionally, these products are exempt from Value Added Tax (VAT) and other import-related charges, facilitating their entry into the Ugandan market. There are no Free Trade Agreements (FTAs) between Uganda and India that specifically affect pharmaceutical tariffs. Furthermore, there are no anti-dumping duties imposed on Actinomycin formulations imported into Uganda.
3Competitive Landscape
India is a significant supplier of Actinomycin formulations to Uganda, accounting for approximately 1.3% of India's total Actinomycin formulation exports, valued at $2.9 million. Other major countries supplying Actinomycin formulations to Uganda include China and various European Union (EU) member states. India's share of Uganda's total Actinomycin imports is substantial, reflecting strong trade relations and competitive pricing. Indian manufacturers are known for offering Actinomycin formulations at competitive prices compared to their counterparts in China and the EU, making them a preferred source for Ugandan importers.
Why Source Actinomycin from India for Uganda?
Manufacturing advantage, cost comparison, supply reliability, and strategic sourcing recommendations
1Why India for Actinomycin — Manufacturing Advantage
India is a global leader in generic pharmaceutical production, accounting for approximately 20% of the global supply by volume as of 2024. The country boasts a robust manufacturing infrastructure with 752 FDA-approved sites, 2,050 WHO-GMP-certified plants, and 286 EDQM-approved facilities, the highest globally. This extensive network includes specialized facilities dedicated to the production of finished dosage forms containing Actinomycin, such as tablets, capsules, and injections. The cost advantages in India stem from economies of scale, a skilled workforce, and competitive raw material sourcing, enabling the production of high-quality Actinomycin formulations at cost-effective prices.
2India vs. China vs. EU — Cost & Quality Comparison
In 2023, India exported $10.4 million worth of medicaments of other antibiotics to Uganda, surpassing China's $8.3 million and the European Union's $3.1 million. This indicates India's competitive pricing and strong market presence. Indian pharmaceutical products are widely accepted in Uganda due to their adherence to international quality standards, including WHO-GMP and FDA approvals. While the EU offers high-quality branded generics, their higher costs often make them less competitive in price-sensitive markets like Uganda. Local Ugandan manufacturers may face challenges in achieving the same economies of scale and regulatory approvals, potentially affecting both cost and quality.
3Supply Reliability & Capacity Assessment
India's pharmaceutical industry has demonstrated a strong track record of supply reliability. The country's manufacturing facilities are equipped with advanced packaging and cold chain capabilities, ensuring the integrity of Actinomycin formulations during transit. While there have been instances of regulatory scrutiny, leading manufacturers have proactively addressed compliance issues and expanded their capacities. For example, in December 2025, Sun Pharma announced a $332 million investment in a new formulations manufacturing facility in Madhya Pradesh to enhance production capacity and meet global demand. Such initiatives underscore the industry's commitment to maintaining a stable supply chain.
4Strategic Sourcing Recommendations
- Dual-Sourcing Strategy: Engage with multiple Indian manufacturers to mitigate risks associated with supply disruptions and ensure a consistent supply of Actinomycin formulations.
- Minimum Order Quantities (MOQs): Negotiate MOQs that align with your demand forecasts. Indian suppliers often offer flexibility, but understanding their production constraints is crucial.
- Payment Terms: Standard payment terms in India-Uganda pharmaceutical trade include letters of credit (LC) and advance payments. Establish clear terms to maintain smooth transactions.
- Supplier Qualification Process: Conduct thorough due diligence, including facility audits, verification of regulatory certifications (e.g., WHO-GMP, FDA approvals), and assessment of quality control systems to ensure supplier reliability.
- Regulatory Compliance: Stay updated on Uganda's National Drug Authority (NDA) requirements to ensure imported Actinomycin formulations meet local regulatory standards.
Supplier Due Diligence Guide — Actinomycin from India
Pre-qualification checklist, document requirements, red flags, and audit guidance for Uganda buyers
1Pre-Qualification Checklist for Uganda Buyers
1. Verify Supplier's Licensing and Registration:
2. Assess Good Manufacturing Practice (GMP) Compliance:
3. Review Product Registration Status:
4. Evaluate Quality Management Systems:
5. Conduct Financial and Supply Chain Assessment:
2Key Documents to Request from Indian Suppliers
1. Certificate of Analysis (CoA):
2. Certificate of Origin (CoO):
3. Good Manufacturing Practice (GMP) Certificate:
4. Stability Data:
5. Batch Manufacturing Records:
6. Drug Master File (DMF):
7. Free Sale Certificate:
8. Insurance Certificates:
3Red Flags & Warning Signs
1. Regulatory Non-Compliance:
2. GMP Certification Issues:
3. Unrealistically Low Pricing:
4. Lack of Stability Data:
5. Limited Export History:
6. Resistance to Audits:
4Factory Audit & Ongoing Monitoring
1. Pre-Audit Desktop Review:
2. On-Site Inspection Focus Areas:
3. Post-Audit Corrective Actions:
4. Annual Re-Qualification Process:
5. Remote Monitoring Options:
Cost Estimates and Timeline:
By meticulously following these guidelines, Ugandan companies can ensure the selection of reliable Indian suppliers for Actinomycin formulations, thereby safeguarding public health and maintaining regulatory compliance.
Frequently Asked Questions — India to Uganda Actinomycin Trade
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which Indian companies export Actinomycin to Uganda?
The leading Indian exporters of Actinomycin to Uganda are ZUVIUS LIFESCIENCES PRIVATE LIMITED, RMPL PHARMA LLP , RMPL PHARMA LLP. ZUVIUS LIFESCIENCES PRIVATE LIMITED holds the largest market share at approximately 88% of total trade value on this route.
Q What is the total value of Actinomycin exports from India to Uganda?
India exports Actinomycin to Uganda worth approximately $37.6K USD across 22 recorded shipments. The average value per shipment is $1.7K USD.
Q Which ports does India use to ship Actinomycin to Uganda?
The most active port of origin is SAHAR AIR CARGO ACC (INBOM4) with 16 shipments. Indian exporters primarily use sea freight for this route, with 74% of shipments going by sea and 21% by air.
Q How long does shipping take from India to Uganda for Actinomycin?
The average transit time for Actinomycin shipments from India to Uganda is approximately 21 days. Sea freight typically takes longer, while air freight can reduce this significantly for urgent orders. Peak shipping activity is observed during April–June.
Q Is the India to Uganda Actinomycin trade route growing?
Yes — this trade corridor has seen an annual growth rate of approximately 18.3% with demand growth tracking at 15.7%. The route is ranked #15 among India's top Actinomycin export destinations globally.
Q How many suppliers are active on the India to Uganda Actinomycin route?
There are currently 4 active Indian suppliers exporting Actinomycin to Uganda. The market is moderately concentrated with ZUVIUS LIFESCIENCES PRIVATE LIMITED accounting for 88% of total shipment value.
Q Who are the main importers of Actinomycin from India in Uganda?
The leading importers of Indian Actinomycin in Uganda include ONCOPHARM SPECIALITY PHARMACY, TO THE ORDER OF INVOICE RAISED TO , INVOICE RAISED TO, FIRST PHARMACY (U) LTD , TO THE ORDER OF INVOICE RAISED TO. ONCOPHARM SPECIALITY PHARMACY is the largest buyer with 3 shipments worth $33.2K USD.
Official References & Regulatory Resources
- India Trade Statistics (DGFT)
- Invest India — Pharma Sector
- WCO HS Nomenclature
- Ministry of Commerce — Pharma Exports
- Pharmexcil
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Route Identification: India to Uganda export trade corridor identified from Indian Customs (DGFT) records for Actinomycin.
- 2.Supplier/Buyer Matching: 4 Indian exporters and 5 importers in Uganda matched using name normalization.
- 3.Value Aggregation: Total export value aggregated from 22 verified shipping bill records. Values are FOB in USD.
- 4.Market Share Analysis: Each supplier and buyer contribution calculated as a percentage of total route value. Statistical normalization applied to ensure accurate representation across varying shipment sizes.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
22 Verified Shipments
4 Indian exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists